CYClipper F. Young

Clipper F. Young

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clipper F. Young has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identifying the Unmet Psychosocial Needs of Individuals Newly Diagnosed With Type 2 Diabetes

    by Elizabeth J. Unni, Clipper Young, Tristan J. Rath, Elizabeth A. Beverly

    OBJECTIVE: Few studies have explored the experiences of individuals newly diagnosed with type 2 diabetes (T2D). This study aimed to characterize these experiences, particularly psychosocial experiences, through in-depth interviews to identify unmet psychosocial needs. RESEARCH DESIGN AND METHODS: This qualitative descriptive study explored 30 individuals’ experiences within 9 months after receiving a T2D diagnosis using a semistructured guide. After independent coding of the transcripts by two researchers, codes were compared and discrepancies resolved through group consensus. This step was followed by a third researcher reviewing all coded data to ensure consistency across the coding framework. Finally, the research team looked for patterns and derived themes from groups of similar codes. RESULTS: Qualitative analysis identified seven themes, reflecting the complexity of adaptation to this chronic condition and underscoring the multifaceted support system required, especially in the early months after the diagnosis: 1) emotional and psychological impacts of the diagnosis, 2) need for additional information and education, 3) time to adapt to lifestyle changes, 4) difficulties and fears in medication management, 5) challenges with the health care system, 6) barriers to social support, and 7) positive aspects of the diagnosis. CONCLUSIONS: The study findings show a gap in primary care where individuals with newly diagnosed T2D need additional psychosocial support in integrating their diagnosis into their everyday lives. Early intervention strategies should be multidimensional, addressing emotional well-being, personalized education, practical lifestyle support, and access to health care services.

  • The Impact of Type 2 Diabetes and Obesity on Hospital Length of Stay After Total Knee Arthroplasty: An HCUP Study

    by Paul W. Musharbash, Jerome B. Torres, Wyland W. Worley, Clipper F. Young

    OBJECTIVE: To evaluate the impact of concurrent type 2 diabetes and obesity on hospital length of stay following total knee arthroplasty at the national level. RESEARCH DESIGN AND METHODS: This retrospective cohort study used the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (2017–2021) to evaluate adults undergoing total knee arthroplasty. After excluding missing data, the sample totaled 474,715 patients. Groups were categorized as concurrent type 2 diabetes and obesity, obesity alone, type 2 diabetes alone, or neither condition. Multivariable linear regression was used to assess the association between metabolic status and length of stay, adjusting for age, sex, race, and socioeconomic quartile. Baseline medical complexity was adjusted using the Elixhauser comorbidity index, excluding diabetes and obesity. RESULTS: Adjusted regression revealed an increased length of stay across groups: concurrent type 2 diabetes and obesity (β = 0.20 days; 95% CI = 0.17–0.22; P < 0.001), type 2 diabetes alone (β = 0.12 days; 95% CI 0.11–0.14; P < 0.001), and obesity alone (β = 0.02 days; 95% CI 0.01–0.04; P = 0.002). CONCLUSIONS: Cumulative metabolic dysfunction significantly compounds inpatient resource use after primary total knee arthroplasty, with type 2 diabetes and obesity leading to extended stays. Notably, the effect of type 2 diabetes alone was approximately five times greater than that of obesity alone, demonstrating that it is the dominant driver of prolonged hospitalization. These findings suggest that cumulative metabolic dysfunction significantly impacts inpatient resource use, highlighting the value of increased preoperative metabolic optimization.

  • Type 2 diabetes and the cardio–renal–metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists

    by Clipper F Young, Namrita George, Alexander Olson, Diana Isaacs

    In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2

  • Artificial intelligence in cardio-kidney-metabolic care: Transforming integrated disease management through data-informed innovation

    by Clipper F. Young, Janice MacLeod

    Artificial intelligence (AI) is rapidly transforming the landscape of chronic medical conditions, such as cardio-kidney-metabolic (CKM) issues linked to type 2 diabetes and obesity. It creates new opportunities to shift from reactive to proactive, data-driven care. Recent advances include predictive algorithms for hypoglycemia and hyperglycemia, decision-support tools for insulin titration, and generative and agentic AI applications that can enhance patient engagement, streamline clinical workflows, and provide personalized education. For individuals with chronic conditions, AI-powered technologies offer hope in reducing disease burden, supporting self-management, and improving quality of life. For clinicians, AI offers opportunities to analyze and interpret large amounts of glucose, medication, and behavioral data, thus supporting personalized care and freeing more time to focus on psychosocial and lifestyle factors. Despite these benefits, challenges remain, such as ensuring equitable access, integrating AI into primary care, building trust among clinicians and patients, and addressing ethical issues related to data use. This review will synthesize current evidence on AI's impact on diabetes and CKM care and education, highlight opportunities for interdisciplinary teams to utilize AI tools, and outline future directions for research and clinical practice. By examining AI's potential and limitations, this article aims to equip clinicians with the knowledge needed to adopt AI-enabled approaches to better manage chronic diseases.


  • Open Access

    Evaluation of the association between history of open chest or abdominal surgery and cardiovascular risks: an NHANES study, January 2007 – March 2020

    by Alexander Olson, David L. Coffman, Clipper F. Young

    Context: The clinical relationship between cardiovascular disease and deleterious surgical outcomes has been extensively examined; however, the relationship between cardiovascular risk and the association with major surgical interventions has yet to be examined at the population level. Previous use of National Health and Nutrition Examination Survey (NHANES) data has investigated the relationship between cardiometabolic risk and a history of bariatric surgery, suggesting that NHANES population data may be a useful tool to uncover a primary association and provide insight into subgroup effects. Objectives: This study attempts to quantify the relationships between cardiovascular risk factors and the history of open-chest or abdominal surgery. Methods: We analyzed de-identified NHANES data from January 2007 through March 2020 for US adults ≥20 years of age selected via stratified multistage sampling (participants with missing data were excluded; Institutional Review Board [IRB] not required). We extracted self-reported history of open-chest/abdominal surgery (binary), seven metabolic/cardiovascular biomarkers (hemoglobin A 1c [HbA 1c ], low-density lipoprotein [LDL], triglycerides, total cholesterol, systolic/diastolic blood pressure [SBP/DBP], high-density lipoprotein [HDL]), and covariates (race/ethnicity, gender, education, insurance, income-to-poverty ratio). Associations were estimated as odds ratios (ORs) utilizing survey-weighted logistic regression in STATA 16 adjusted for all covariates (two-sided α=0.05), with subpopulation logistic models for subgroup analyses by HbA 1c . Results: The elevated HbA 1c level was the only variable that was statistically significant, with an OR of 1.14 (95 % confidence interval [CI], 1.06–1.23). Secondary subgroup analyses demonstrated differential impacts: Non-Hispanic White, individuals without insurance, those with a lower income-to-poverty ratio, females, and individuals with less than a ninth-grade education or a high school/General Education Development (GED) equivalent were more likely to have a surgical history as HbA 1c levels increased. Conclusions: A significant association exists between elevated HbA 1c levels and a history of open-chest or abdominal surgery. Specific subgroups are at greater risk and may be disproportionately affected by the downstream consequences of higher HbA 1c levels.


  • The Critical Role of Diabetology Pharmacists in Improving Cardiovascular-Kidney-Metabolic Care and Outcomes

    by Clipper F. Young, Katelyn O’BRien, Joshua J. Neumiller, Diana Isaacs, Jay H. Shubrook, Jennifer N. Clements

    Diabetes and its related conditions have become increasingly complex and prevalent. Furthermore, diabetes is closely associated with multiple comorbidities and complications. Helping people manage these interconnected disorders requires a team approach, with frequent touchpoints and optimal guidance. As numerous treatments and technologies can enhance diabetes care, these modalities also increase the complexity of clinical diabetes management. A skilled interprofessional team represents a best practice model in diabetes care. Pharmacists have played a central and critical role in diabetes care, consistently improving patient outcomes. Ample evidence has suggested that pharmacist-led treatment protocols improve diabetes care and patient outcomes, particularly given the shortage of specialized pharmacists in the field. This highlights the need to establish a structured postgraduate training consortium and to recognize diabetology pharmacists, a newly emerging classification of clinical pharmacists with training and experience in diabetology (a newly recognized medical subspecialty). This article outlines a strategic plan to set the foundation for bridging current gaps and introducing the much-needed voice of pharmacists in diabetology. This plan involves partnering with the American College of Diabetology (ACD) to convene a consortium of clinical pharmacy experts who focus on diabetes to institute a call to action and design a set of competencies for credentialing ACD-certified diabetology pharmacists.

  • Open Access

    Community Health Empowerment Through Clinical Pharmacy: A Single-Arm, Post-Intervention-Only Pilot Implementation Evaluation

    by Clipper F. Young, Casey Shubrook, Cherry Myung, Andrea Rigby, Shirley M. T. Wong

    Background: The Pharm2Home Initiative’s Community Health Arm adopts a health-equitable approach to chronic disease education and medication therapy management (MTM). We serve senior residents of Solano County, California, who live in affordable housing and have limited financial resources. Aim: This evaluation assesses the uptake of chronic disease management recommendations provided by clinical pharmacists during MTM sessions at community events. Methods: The program engaged clinical pharmacists to provide tailored education and healthcare interventions in senior housing facilities. The goal was to empower seniors to manage their health effectively. The sessions covered various topics, including expired or duplicated medications, incorrect medication use, consultations on medication management, immunizations, and lifestyle adjustments. Results: Over an 18-month period, from January 2022 to August 2023, the program involved 65 participants across ten community health events. These events provided approximately 65 h of direct intervention. Many participants reported significant improvements in understanding their treatment plans and navigating their health needs more confidently. Feedback from 60 seniors after the sessions indicated that 88% felt much better informed about their medications, and 75% expressed that their concerns were addressed extremely well. Conclusions: These outcomes demonstrate the importance of clinical pharmacist-led interventions in improving seniors’ medication use and chronic disease management. The initiative’s approach advocates for integrating clinical pharmacists into community health settings, suggesting a scalable model for enhancing person-centered care. However, further studies are necessary to assess the long-term impacts of these interventions and explore their effectiveness across diverse age groups and more complex conditions.

  • Open Access

    Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?

    by Clipper F. Young, Neeka Farnoudi, Jenny Chen, Jay H. Shubrook

    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were once known as a class of glycemic-lowering agents to treat type 2 diabetes. As the evolving evidence from recent cardiorenal trials on these agents has shown—e.g., EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS Program, DAPA-CKD—disclosing their benefits beyond glycemic management, SGLT-2 inhibitors have stimulated a shift in the management of T2DM and its comorbidities, specifically preventing cardiovascular events in people with ASCVD, preventing heart failure hospitalizations, and delaying the progression of chronic kidney disease. As a result, their usage beyond glycemic management has been included in clinical practice guidelines. Although SGLT-2 inhibitors have shown promising results in cardiorenal outcomes, patients have not had equal access to these agents, at least in the United States, suggesting a systemic issue of health inequity. This review article explores the mechanisms by which cardiorenal benefits are offered, the results of the landmark clinical trials for these agents, and their place in therapy.


  • Contributors

    by Sudhir BagaRao, Gül Erdemli, Monica L. Hawley, Jacob Herrmann, Foad Kabinejadian, David W. Kaczka, Kah Meng Loh, Sandeep Mukherjee, David Chee-Eng Ng, Eddie Yin Kwee Ng, et al.